- Mallinckrodt (NYSE:MNK) -14% on FDA rejection of terlipressin for type of kidney failure.
- More news on: Mallinckrodt plc, Taoping Inc., Nikola Corporation, Stocks on the move, , Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Mallinckrodt plc Company Name:
MNK Stock Symbol:
Market:
Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations PR Newswire Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First a...
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI,” or “the Company”) today announced that Chairman and Chief Executive Officer Douglas T. Dietrich, Chief Financial Officer Erik Aldag, and Vice President of Investor Relations Lydi...
Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan PR Newswire Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust ...